Yes you're correct that there is a long road ahead before the compound is determined to be safe and effective for intravenous use. On the other hand, it has been proven effective as a topical antiseptic (recent burn infection trial), and cure of one case of previously untreatable sinus infection (superbug) via the TGA Special Access Scheme.
So even if RCE 327 fails for safety or effectiveness for intravenous use, it is much less likely that it will fail as a topical antibacterial treatment, and this market alone is likely to be worth many times RCE's current value.
Ann: Positive Safety Data from Third Cohort of PI Clinical Trial, page-37
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $125.2M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 52.0¢ | $1.969K | 3.714K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 341 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 49936 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |